Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01525095 · ClinicalTrials.gov registry record
Detecting Infections Rapidly and Easily for Candidemia Trial (DIRECT)
A clinical trial of Candidemia, sponsored by T2 Biosystems.
- Completed
- Registry status
- 700
- Enrollment target
- 5
- Study locations
NCT01525095: Completed study of Candidemia, sponsored by T2 Biosystems.
NCT01525095 is a study of Candidemia that has completed, run by T2 Biosystems. The registered enrollment target is 700 participants, above the 327-participant average among 8 other Candidemia trials with a reported enrollment target (114% higher). The trial reports 5 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01525095, a study of Candidemia, has completed, sponsored by T2 Biosystems.
- COMPLETED
- Registry status
- 700 participants
- Enrollment target
- 5
- Study locations
Study Summary
The purpose of this study is to assure the uniform collection, handling, storage and transport of patient whole blood specimens and associated information to support validation of the T2 Candida Assay.
Primary Outcome
Number of Candida Positive patients based on concordant, sequential blood culture results and a positive T2 signal
Conditions Studied
Study Locations (5)
Alabama
- University of Alabama at Birmingham - Birmingham
California
- University of California San Francisco - San Francisco
Kentucky
- University of Kentucky - Lexington
Michigan
- Henry Ford Hospital - Detroit
Texas
- University of Houston College of Pharmacy - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 700 participants |
| Start Date | 2012-01 |
| Est. Completion | 2014-03 |
What the finished NCT01525095 record still lists
NCT01525095 is an observational study that tracks outcomes without assigning an intervention. The registered 700 participants enrollment target is mid-sized for trials with a published cap, above the 327-participant average among 8 other Candidemia trials with a reported enrollment target (114% higher).
The record links to 1 condition, with Candidemia appearing as the primary indexed condition, and to 0 interventions.
NCT01525095 lists 5 locations in 5 states (Alabama, California, Kentucky).
Frequently Asked Questions
What is clinical trial NCT01525095 about?
NCT01525095 is a clinical study titled "Detecting Infections Rapidly and Easily for Candidemia Trial (DIRECT)". The purpose of this study is to assure the uniform collection, handling, storage and transport of patient whole blood specimens and associated information to support validation of the T2 Candida Assay.
What is the current status of trial NCT01525095?
This trial is currently completed. The enrollment target is 700 participants. The study started on 2012-01. Estimated completion is 2014-03.
What conditions does trial NCT01525095 study?
This clinical trial studies the following conditions: Candidemia.
Who is sponsoring clinical trial NCT01525095?
This trial is sponsored by T2 Biosystems, which has 7 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01525095 being conducted?
This trial has 5 study locations across Alabama, California, Kentucky, Michigan, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Candidemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01525095's enrollment target sits among peer trials
700 1st of 8 higher than 8 of 8 other Candidemia trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Candidemia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Phase 3 Efficacy and Safety Study of Fosmanogepix for the Treatment of Adult Participants With Candidemia and/or Invasive Candidiasis.
RECRUITING · Phase 3
-
Safety and Efficacy of Interferon-Gamma 1b in Patients With Candidemia
RECRUITING · Phase 2
-
Study of Rezafungin Compared to Standard Antimicrobial Regimen for Prevention of Invasive Fungal Diseases in Adults Undergoing Allogeneic Blood and Marrow Transplantation
ACTIVE NOT RECRUITING · Phase 3
-
Study of Mycamine® in Children With Fungal Infections to Evaluate Safety and Blood Levels of the Drug
COMPLETED · Phase 1
-
Isavuconazole (BAL8557) in the Treatment of Candidemia and Other Invasive Candida Infections
COMPLETED · Phase 3
-
Study of Micafungin in Patients With Invasive Candidiasis or Candidemia
COMPLETED · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00900419 · 700 participants
Biomarkers in Patients With Respiratory Tract Dysplasia or Lung Cancer, Head and Neck Cancer, or Aerodigestive Tract Cancer and in Normal Volunteers
- NCT01804686 · 700 participants · Phase 3
A Long-term Extension Study of PCI-32765 (Ibrutinib)
- NCT02107989 · 700 participants
Noninvasive Pre-surgical Evaluation of Patients With Focal Epilepsy and Establishment of a Normative Imaging Database
- NCT02129543 · 700 participants
Immune Reconstitution in Stem Cell Transplant Recipients
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia